Skip to main content

Site notifications

LAMZEDE Chiesi Australia Pty Ltd

Product name
LAMZEDE
Accepted date
Apr-2024
Active ingredients
Velmanase alfa
Proposed indication
For the treatment of alpha-mannosidosis.
Application type
A (new medicine)
Publication date
Apr-2024
Orphan drug
Sponsors receive a fee waiver to help bring medicines for a small population to market.

Help us improve the Therapeutic Goods Administration site